You can buy or sell AXSM and other stocks, options, ETFs, and crypto commission-free!
Axsome Therapeutics, Inc. Common Stock, also called Axsome Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Read More Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Axsome Therapeutics, - 4 Stocks Breaking Out On Earnings & Other News
Here are four stocks to watch with strong technical momentum fueled by earnings and other news. Axsome Therapeutics, Inc. (NASDAQ: AXSM) gained 39 cents to $19.54 on Tuesday on 1.4 million shares. The biotech company announced Monday that the FDA granted Breakthrough Therapy Designation for its therapy for major depressive disorder. The stock has been a huge climber this year, starting the year under $3. After flagging in the last week, it looks poised to continue the uptrend, with the next target towards ...
What's in Store for Axsome (AXSM) This Earnings Season?
Axsome Therapeutics, Inc. AXSM is scheduled to report first-quarter 2019 earnings results on May 9, 2019, before the market opens. The company's performance over the trailing four quarters has been encouraging with its earnings having surpassed expectations twice while meeting the same just once. The average trailing four-quarter beat is 3.03%. In the las t report ed quarter, Axsome delivered a positive surprise of 3.03%. Shares of Axsome have skyrocketed 579.1% so far this year, outperforming the industr...
Health Care Sector Update for 05/06/2019: ESPR, AXSM, CANF, JNJ, PFE, ABT, MRK, AMGN
Top Health Care Stocks: JNJ: -1.05% PFE: -0.89% ABT: -1.83% MRK: -1.54% AMGN: -1.10% Monday pre-market saw lower health care majors. Stocks moving on news include: (+) Esperion Therapeutics ( ESPR ), which was more than 11% higher after the the Food and Drug Administration accepted its new drug applications (NDAs) for bempedoic acid and the bempedoic acid/ezetimibe combination tablet for the treatment of low-density lipoprotein cholesterol (LDL-C) in patients who need additional LDL-C lowering despi...
Expected Aug 7, Pre-Market